GlobalData epidemiologists project TB cases across the 16 major markets to reach 4.5 million by 2033.

I hope I got your attention with my last post about the Pacific Health Summit and the acute global threat of Multi-Drug Resistant Tuberculosis (MDR-TB). All of the issues around innovation in public ...

Phase 3 STAND Trial Launches to Advance PaMZ through Final Stage of Testing A new tuberculosis (TB) drug regimen designed to improve options for TB therapy eliminated more bacteria from sputum than ...

In a recent review published in the Open Forum Infectious Diseases journal, researchers reported on the evolution of multidrug-resistant tuberculosis (MDR-TB) therapy. Study: At long last: short, ...

Please provide your email address to receive an email when new articles are posted on . The National Institute of Allergy and Infectious Diseases, part of the NIH, has launched a trial investigating ...

FRANKLIN LAKES, N.J., April 13, 2021 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that its BD MAXTM Molecular Multi-Drug ...

A new partnership announced today will increase efforts to coordinate the development of complementary novel tools to fight TB, including drug-resistant TB, and identify emerging drug resistance ...

Mumbai: Mumbai has recorded a 28% drop in multi-drug resistant tuberculosis (MDR-TB) cases over the last three years, with annual resistant cases falling from 5,698 in 2022 to 4,080 in 2025.A total of ...

Last month I attended the Pacific Health Summit in Seattle. It is a pretty exclusive venue (aspiring to be the “Davos of Health Care”) attended by senior representatives from the world of health care ...

Add Yahoo as a preferred source to see more of our stories on Google. Today It has been several years since a new tuberculosis (TB) drug advanced into Phase III trials, but momentum in the field is ...